S2P Overzicht aandelen Simcere Pharmaceutical Group Limited houdt zich bezig met onderzoek, ontwikkeling, productie en verkoop van farmaceutische producten voor distributeurs en apotheekketens en andere farmaceutische fabrikanten in China. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Simcere Pharmaceutical Group Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Simcere Pharmaceutical Group Historische aandelenkoersen Huidige aandelenkoers HK$0.81 52 Week Hoogtepunt HK$0.89 52 Week Laag HK$0.57 Bèta 0.44 1 maand verandering 0% 3 maanden verandering 10.20% 1 Jaar Verandering 5.19% 3 jaar verandering -16.92% 5 jaar verandering n/a Verandering sinds IPO -44.14%
Recent nieuws en updates
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25 Meer updates bekijken
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022) Apr 26
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Sep 25
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold €271k worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Co-Founder recently sold €360k worth of stock May 01
Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021) Apr 19
Investor sentiment improves as stock rises 19% Apr 13
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Investor sentiment deteriorated over the past week Jan 20
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Now 30% undervalued Jan 18
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Co-Founder recently bought €957k worth of stock Jan 11 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Investor sentiment improved over the past week Dec 30
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 03
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 15
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Investor sentiment improved over the past week Jul 09
Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022 Jun 25
Upcoming dividend of CN¥0.15 per share Jun 21 Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021 Jun 02
Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer May 26
Investor sentiment improved over the past week May 18
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 (3Cl) Issued by the National Medical Products Administration May 17
CFO & Executive Director recently bought €66k worth of stock Apr 30
Full year 2021 earnings released: EPS: CN¥0.58 (vs CN¥0.28 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Products Administration of China to Conduct Clinical Trials Apr 01
Investor sentiment improved over the past week Mar 21
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease Mar 01
Simcere Pharmaceutical Group Announces Primary Endpoint Met in Phase III Clinical Trial of Trilaciclib in Chinese Patients with Small Cell Lung Cancer Feb 24
Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021 Feb 22
Simcere Pharmaceuticals Announces Appointment of Bijoyesh Mookerjee as Chief Medical Officer, Oncology Feb 08
Simcere Pharmaceutical Group Limited Announces the Approval of Investigational New Drug for SIM0235 Issued by U.S. Food and Drug Administration Jan 31
Investor sentiment improved over the past week Jan 18
Center for Drug Evaluation of the National Medical Products Administration of China Includes Simcere Pharmaceutical Group Limited's Trilaciclib Injection as a Priority Review Drug Dec 23 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0235 Issued by National Medical Products Administration
Simcere Pharmaceutical Group Limited Announces Conditional Approval on the Marketing of Enweida (Envafolimab) in China by The national Medical Products Administration Nov 27
Investor sentiment improved over the past week Nov 19
Co-Founder recently bought €127k worth of stock Nov 02 Rendement voor aandeelhouders S2P DE Pharmaceuticals DE Markt 7D -2.4% -0.3% -0.3% 1Y 5.2% -17.0% 7.0%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: S2P overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -17 % opleverde.
Rendement versus markt: S2P presteerde slechter dan German Market , dat het afgelopen jaar een rendement van 7 % opleverde.
Prijsvolatiliteit Is S2P's price volatile compared to industry and market? S2P volatility S2P Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: S2P heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van S2P is het afgelopen jaar stabiel geweest.
Over het bedrijf Simcere Pharmaceutical Group Limited houdt zich bezig met onderzoek, ontwikkeling, productie en verkoop van farmaceutische producten voor distributeurs en apotheekketens en andere farmaceutische fabrikanten in China. Het bedrijf richt zich op verschillende therapeutische gebieden, waaronder oncologie, centraal zenuwstelsel, auto-immuun, anti-infectie, cardiovasculair en andere. De belangrijkste producten zijn Sanbexin, een geconcentreerde oplossing van edaravone en dexborneol voor injectie; Endostar, een injectie van recombinant humaan endostatine; ENWEIDA, een injectie van envafolimab; COSELA, een trilaciclibhydrochloride voor injectie; Iremod, een iguratimod-tablet; en XIANNUOXIN, een simnotrelvir tablet/ritonavir tablet.
Meer tonen Simcere Pharmaceutical Group Limited Samenvatting Hoe verhouden de winst en inkomsten van Simcere Pharmaceutical Group zich tot de beurswaarde? S2P fundamentele statistieken Marktkapitalisatie €2.09b Inkomsten(TTM ) -€145.12m Inkomsten(TTM ) €834.62m
2.5x P/S-verhouding
-14.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) S2P resultatenrekening (TTM ) Inkomsten CN¥6.34b Kosten van inkomsten CN¥1.45b Brutowinst CN¥4.88b Overige uitgaven CN¥5.99b Inkomsten -CN¥1.10b
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.44 Brutomarge 77.05% Nettowinstmarge -17.39% Schuld/Eigen Vermogen Verhouding 14.5%
Hoe presteerde S2P op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
2.5% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/26 00:18 Aandelenkoers aan het einde van de dag 2024/12/23 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Simcere Pharmaceutical Group Limited wordt gevolgd door 16 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
Toon 13 meer analisten 